ENDPOINTS

Pliant calls it quits on Phase 2b IPF study

Pliant Therapeutics has officially discontinued a mid-stage study of its chronic lung disease treatment, less than a month after the trial's safety board recommended a halt. The South San Francisco biotech

Mar 3, 2025 - 21:22
 0
Pliant calls it quits on Phase 2b IPF study
Pliant Therapeutics has officially discontinued a mid-stage study of its chronic lung disease treatment, less than a month after the trial's safety board recommended a halt. The South San Francisco biotech
Read More

Tags:

Previous Article

'Extraordinary' timber circle discovered in Denmark is roughly the same age as S...

Next Article

US science is under threat ― now scientists are fighting back

Related Posts

Cerebral CEO David Mou has stepped down

Cerebral CEO David Mou has stepped down

Mar 3, 2025  0

Court orders CVS to comply with the FTC’s PBM-related investigation

Court orders CVS to comply with the FTC’s PBM-related i...

Feb 26, 2025  0

Achira raises $33M Nvidia-backed seed round, blending AI and physics in biotech

Achira raises $33M Nvidia-backed seed round, blending A...

Feb 21, 2025  0